Palladium Partners LLC Raises Holdings in CVS Health Corp (CVS)

Palladium Partners LLC boosted its holdings in shares of CVS Health Corp (NYSE:CVS) by 2.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 82,179 shares of the pharmacy operator’s stock after purchasing an additional 1,757 shares during the period. Palladium Partners LLC’s holdings in CVS Health were worth $6,682,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Fieldpoint Private Securities LLC grew its position in CVS Health by 333.3% during the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares during the last quarter. Arcadia Investment Management Corp MI grew its position in CVS Health by 119.6% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new position in CVS Health during the 2nd quarter worth $119,000. Gemmer Asset Management LLC grew its position in CVS Health by 15.3% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after purchasing an additional 200 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new position in CVS Health during the 2nd quarter worth $155,000. 81.69% of the stock is currently owned by institutional investors.

Shares of CVS Health Corp (CVS) opened at $79.86 on Friday. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. CVS Health Corp has a 52 week low of $66.45 and a 52 week high of $84.00. The company has a market cap of $80,897.54, a PE ratio of 13.99, a P/E/G ratio of 1.26 and a beta of 0.90.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion during the quarter, compared to analysts’ expectations of $46.17 billion. During the same quarter last year, the business earned $1.64 earnings per share. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. research analysts forecast that CVS Health Corp will post 5.89 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 2nd. Investors of record on Wednesday, January 24th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.50%. The ex-dividend date of this dividend is Tuesday, January 23rd. CVS Health’s dividend payout ratio (DPR) is 41.32%.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares in the company, valued at $1,166,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.61% of the stock is owned by company insiders.

Several brokerages have issued reports on CVS. Vetr downgraded shares of CVS Health from a “hold” rating to a “sell” rating and set a $76.66 price objective on the stock. in a research report on Tuesday, January 16th. Cowen reaffirmed an “outperform” rating and issued a $99.00 target price (up previously from $81.00) on shares of CVS Health in a report on Thursday. ValuEngine downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. SunTrust Banks lifted their target price on shares of CVS Health to $90.00 and gave the company a “buy” rating in a report on Friday, January 5th. Finally, Morgan Stanley raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 target price on the stock in a report on Friday, January 5th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $87.25.

WARNING: “Palladium Partners LLC Raises Holdings in CVS Health Corp (CVS)” was first published by Week Herald and is the property of of Week Herald. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://weekherald.com/2018/01/21/palladium-partners-llc-raises-holdings-in-cvs-health-corp-cvs.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply